MoonLake Reports Favorable Long-Term Results for Sonelokimab in HS Trials

MoonLake Immunotherapeutics has announced positive 52-week data from its Phase 3 VELA program for sonelokimab in treating hidradenitis suppurativa (HS). The results demonstrated continued and enhanced improvements in clinical scores, with a significant percentage of patients achieving high levels of response. The company plans to discuss these findings further at an upcoming investor event.